We are live on ! Find out more
LGND icon

Ligand Pharmaceuticals

357 hedge funds and large institutions have $4.15B invested in Ligand Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 133 increasing their positions, 115 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 43

22% more call options, than puts

Call options by funds: $8.48M | Put options by funds: $6.95M

16% more repeat investments, than reductions

Existing positions increased: 133 | Existing positions reduced: 115

7% more capital invested

Capital invested by funds: $3.89B → $4.15B (+$264M)

2% more funds holding

Funds holding: 349357 (+8)

0% more funds holding in top 10

Funds holding in top 10: 88 (0)

0.18% less ownership

Funds ownership: 104.47%104.29% (-0.18%)

Holders
357
Holders Change
+8
Holders Change %
+2.29%
% of All Funds
4.39%
Holding in Top 10
8
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.1%
New
59
Increased
133
Reduced
115
Closed
43
Calls
$8.48M
Puts
$6.95M
Net Calls
+$1.54M
Net Calls Change
-$3.42M
Name Holding Trade Value Shares
Change
Change in
Stake
LPL Financial
126
LPL Financial
California
$1.64M +$779K +3,938 +92%
II
127
Ishara Investments
California
$1.64M +$1.62M +8,200 New
P8IP
128
Pier 88 Investment Partners
California
$1.6M -$103K -520 -6%
SPS
129
Susquehanna Portfolio Strategies
Pennsylvania
$1.59M +$44.5K +225 +3%
Wellington Management Group
130
Wellington Management Group
Massachusetts
$1.58M -$103K -520 -6%
CC
131
Cornerstone Capital
California
$1.57M +$542K +2,739 +54%
Marshall Wace
132
Marshall Wace
United Kingdom
$1.5M +$1.48M +7,505 New
AQR Capital Management
133
AQR Capital Management
Connecticut
$1.48M +$451K +2,279 +44%
JFG
134
Jefferies Financial Group
New York
$1.46M +$1.45M +7,315 New
AAM
135
Advisors Asset Management
Colorado
$1.39M +$715K +3,612 +108%
BMSSC
136
B. Metzler seel. Sohn & Co
Germany
$1.37M
State of New Jersey Common Pension Fund D
137
State of New Jersey Common Pension Fund D
New Jersey
$1.34M +$7.32K +37 +0.6%
Susquehanna International Group
138
Susquehanna International Group
Pennsylvania
$1.34M +$256K +1,294 +24%
Citadel Advisors
139
Citadel Advisors
Florida
$1.32M +$896K +4,530 +219%
AssetMark Inc
140
AssetMark Inc
California
$1.31M +$75K +379 +6%
Squarepoint
141
Squarepoint
New York
$1.28M +$1.27M +6,394 New
Corient Private Wealth
142
Corient Private Wealth
Florida
$1.27M -$1.9M -9,599 -60%
QCM
143
Quantinno Capital Management
New York
$1.24M +$639K +3,228 +108%
IIM
144
INTECH Investment Management
Florida
$1.22M -$296K -1,498 -20%
Barclays
145
Barclays
United Kingdom
$1.2M -$5.34M -26,974 -82%
SO
146
STRS Ohio
Ohio
$1.16M -$59.4K -300 -5%
FAM
147
Fred Alger Management
New York
$1.14M +$381K +1,927 +51%
QCG
148
Quadrant Capital Group
Ohio
$1.13M +$198 +1 +0%
AB
149
Amalgamated Bank
New York
$1.13M -$5.93K -30 -0.5%
Man Group
150
Man Group
United Kingdom
$1.13M +$434K +2,194 +64%

LGND Hedge Fund Activity: Q1 2026 in Review

357 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2026, worth a combined $4.15B — up 6.8% from $3.89B a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new LGND positions and 43 closed out — a net gain of 16 holders — while 133 added to existing stakes and 115 trimmed.

The largest buyer was Invesco, adding an estimated $60.8M. The largest seller was UBS AM, cutting an estimated $29.8M.

  • 357 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2026, up from 349 in Q4 2025.
  • Funds reported $4.15B of Ligand Pharmaceuticals stock for Q1 2026, up 6.8% quarter-over-quarter.
  • 59 funds opened new Ligand Pharmaceuticals positions in Q1 2026 and 43 closed out, a net change of +16 holders.
  • The largest Ligand Pharmaceuticals buyer in Q1 2026 was Invesco, an estimated $60.8M added.
  • The largest Ligand Pharmaceuticals seller in Q1 2026 was UBS AM, an estimated $29.8M sold.

Based on aggregated 13F filings for Q1 2026.